Compare Summit Therapeutics Inc (SMMT) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Summit Therapeutics Inc trades at $17.45 (market cap $13.71B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.91 (market cap $2.03B). The key difference: Summit Therapeutics Inc is far larger — about 6.8× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| SMMT | TMF | |
|---|---|---|
Market Cap | $13.71B | $2.03B |
Volume | 6,173,057 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $26.38 | $44.14 |
52-Week Low | $12.43 | $25.19 |
Typical Hold Time | 16 Days | 28 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.93, up 2.75% with elevated volume. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF saw increased trading interest recently, with support at $25 and resistance at $26.
As a leveraged ETF tracking long-term Treasuries, TMF's outlook hinges on interest rate trends. Opportunities exist if rates fall, but risks include rate hikes and volatility decay. Investors should monitor Fed policy for directional cues amid current bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
